Trading Stocks
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
DOW +6% power hour
Nice one
TRBCQ +47%
VSTN +25%, looking for .15
Maybee not ready yet, I see they buy vs sells is about 50/50 now, smells a little dilutive but I saw this puppy go to .004 on the last mega move, seems its building up!
VSTN moving fast +15%
Another 1 just filed too, luxyq
James JayCee
released on Wednesday, 3/11/09, a 1-document, 2-page '3'
Initial Statement of Beneficial Ownership of Securities -- Form 3
for the period ended Wednesday, 3/11/09
filed as of Wednesday, 3/11/09, with respect to
Cinemastar Luxury Theaters Inc [ formerly Nickelodeon Theater Co Inc ]
BSTI somethings up!
BSTI somethings up!
OMG that Jaycee James just Filed about 11 more form 3's
ASAP
ADMH
AGMB
AMKB
NETW-grey
VFTR
CPMG
A little slow here today!
PHMB over $43,000 in $$$ Volume now, WOW!!!
PHMB +33% 67 mil shares bought vs 10 mil sold, $28,000 in dollar Volumr!!
http://ih.advfn.com/p.php?pid=trades&cb=1236783413&symbol=NO^PHMB&java_vm=sun&java_vm_ver=1.6.0_11&fp=10.0.22
PHMB +33% 67 mil shares bought vs 10 mil sold, $28,000 in dollar Volumr!!
http://ih.advfn.com/p.php?pid=trades&cb=1236783413&symbol=NO^PHMB&java_vm=sun&java_vm_ver=1.6.0_11&fp=10.0.22
67 Mil shares bought vs 10 mil sold
http://ih.advfn.com/p.php?pid=trades&cb=1236783413&symbol=NO^PHMB&java_vm=sun&java_vm_ver=1.6.0_11&fp=10.0.22
F*ck, fingers too fast, lol
PHMB over $24,000 in $$ Volume already, its gonna go!!
PHMB over $24,000 in $$ Volume already, its gonna go!!
PMHB over $22,000 in $$ Volume already, its gonna go!!
MYNG +45% 2 x 10 day average volume
PHMB News, Volume alert, .0003
PHMB Volume Alert .0003 + News
http://finance.yahoo.com/news/PharmaCom-BioVet-Inc-Expands-iw-14602340.html
PharmaCom BioVet, Inc. Expands On Strategic Alliances
Wednesday March 11, 2009, 7:30 am EDT
Buzz up! Print RALEIGH, NORTH CAROLINA--(MARKET WIRE)--Mar 11, 2009 -- PharmaCom BioVet, Inc. (Other OTC:PHMB.PK - News) is pleased to announce that discussions are ongoing with companies specializing in our field area of focus. It is anticipated that strategic partnerships of this nature will greatly enhance the potential of the business model designed and now being implemented by management.
"We are realising the importance and significance of the strategic partnering with companies with which we have a high degree of synergy", stated Mr. Gary Berthold, President of PharmaCom BioVet, Inc.
In order to advance the business model of creating a nationwide network of Veterinary Oncology Treatment Centers, the company will research and engage in these partnering opportunities in the near future.
About Us:
PharmaCom BioVet, Inc. is quickly positioning itself to becoming the leader in specialized veterinary oncology (cancer treatment facilities for animals). PHMB management is planning the rollout of specialized Veterinary Oncology Treatment Centers that will be strategically located throughout the United States. PHMB has licensed a series of proprietary devices and compounds that will enable animals suffering from cancer a potentially greater life expectancy and decreased suffering.
On behalf of the Board of Directors,
Mr. Gary Berthold
DISCLOSURE:
"Safe Harbour" statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that are subject to risk and uncertainties, including, but not limited to, the impact of competitive products, product demand, market acceptance risks, fluctuations in operating results, political risk and other risks detailed from time to time in PharmaCom BioVet, Inc.'s filings with the Securities and Exchange Commission. These risks could cause PharmaCom BioVet, Inc.'s actual results to differ materially from those expressed in any forward-looking statements made by, or on behalf of, PharmaCom BioVet, Inc.
Contact:
Contacts:
PHMB Volume Alert .0003 + News
http://finance.yahoo.com/news/PharmaCom-BioVet-Inc-Expands-iw-14602340.html
PharmaCom BioVet, Inc. Expands On Strategic Alliances
Wednesday March 11, 2009, 7:30 am EDT
Buzz up! Print RALEIGH, NORTH CAROLINA--(MARKET WIRE)--Mar 11, 2009 -- PharmaCom BioVet, Inc. (Other OTC:PHMB.PK - News) is pleased to announce that discussions are ongoing with companies specializing in our field area of focus. It is anticipated that strategic partnerships of this nature will greatly enhance the potential of the business model designed and now being implemented by management.
"We are realising the importance and significance of the strategic partnering with companies with which we have a high degree of synergy", stated Mr. Gary Berthold, President of PharmaCom BioVet, Inc.
In order to advance the business model of creating a nationwide network of Veterinary Oncology Treatment Centers, the company will research and engage in these partnering opportunities in the near future.
About Us:
PharmaCom BioVet, Inc. is quickly positioning itself to becoming the leader in specialized veterinary oncology (cancer treatment facilities for animals). PHMB management is planning the rollout of specialized Veterinary Oncology Treatment Centers that will be strategically located throughout the United States. PHMB has licensed a series of proprietary devices and compounds that will enable animals suffering from cancer a potentially greater life expectancy and decreased suffering.
On behalf of the Board of Directors,
Mr. Gary Berthold
DISCLOSURE:
"Safe Harbour" statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that are subject to risk and uncertainties, including, but not limited to, the impact of competitive products, product demand, market acceptance risks, fluctuations in operating results, political risk and other risks detailed from time to time in PharmaCom BioVet, Inc.'s filings with the Securities and Exchange Commission. These risks could cause PharmaCom BioVet, Inc.'s actual results to differ materially from those expressed in any forward-looking statements made by, or on behalf of, PharmaCom BioVet, Inc.
Contact:
Contacts:
VSTN +74%
Yes sir, been trying to relay the same!
VSTN +64%
VSTN +64%
VSTN +53%
UPDATE 2-Visteon makes $16 mln bond interest payment
http://www.reuters.com/article/rbssConsumerGoodsAndRetailNews/idUSN1052091520090310
Tue Mar 10, 2009 1:17pm EDT Email | Print | Share| Reprints | Single Page[-] Text [+]
Market News
World stocks bounce after falls | Video
Wall St rallies as banks boost sentiment
Oil above $47, OPEC and inventories in focus
More Business & Investing News... * Visteon makes interest payment
* Will manage through challenging environment
* Shares dip fractionally to 3.6 cents (Adds analyst's remarks, Ford comments background, bylines)
By David Bailey and Poornima Gupta
DETROIT, March 10 (Reuters) - Auto parts maker Visteon Corp(VSTN.PK), struggling amid the downturn in the auto industry, made a $16 million bond interest payment on Tuesday, a spokesman said.
"We continue to focus on managing through the current challenging operating environment," spokesman Jim Fisher said.
Visteon warned in February it was uncertain of staying in compliance with its debt covenants and was considering selling or eliminating some operations to raise cash.
Fitch said on Monday it thought a default by Visteon was imminent or inevitable, saying the supplier had "virtually no access" to outside capital.
Visteon, whose shares have plunged to 3.5 cents, has been among suppliers that have been considered at risk for bankruptcy by industry and debt analysts.
"All of their efforts have been overwhelmed," said Kip Penniman, credit analyst at KDP Investment Advisers. "I really thought they would file for Chapter 11 before they made this payment," he said.
Penniman, who has followed Visteon since its spinoff by Ford Motor Co (F.N) in 2000, said the interest payment may have been made for several reasons.
Visteon may have been unable to negotiate bankruptcy financing, it may be banking on support from Ford or the U.S. government, it could be attempting to sell all or part of the company or management may believe it can survive the downturn, Penniman said.
Ford spokesman Todd Nissen said Visteon was still a key supplier for Ford. He declined to say whether Ford had provided any assistance to Visteon, saying that Ford would not comment on any private dealings with its suppliers.
"We are in regular conversations with them," Nissen said. "If it makes sense for is to provide assistance to a supplier, we would do it."
Visteon also said in February it planned additional job cuts to help it cope with the downturn. It eliminated 9,300 jobs in 2008.
With automakers slashing North American production sharply from the fourth quarter of 2008 onward, the pressure on auto parts suppliers such as Visteon has been increasing. Continued...
Nice, will do!
VSTN moving nicely on good news! What you watching/playing?
PHMB .0003 gettin smoked, volume alert, News!!!
PHMB News out this morning
Press Release Source: PharmaCom BioVet, Inc.
PharmaCom BioVet, Inc. Provides Update On Corporate Development
Tuesday March 10, 10:24 am ET
RALEIGH, NORTH CAROLINA--(MARKET WIRE)--Mar 10, 2009 -- PharmaCom BioVet, Inc. (Other OTC:PHMB.PK - News) is pleased to provide shareholders with a corporate update on the company's development within the field of specialized veterinary oncology. As previously announced, the company is undergoing a strategic plan establishing Veterinary Oncology Treatment Centers on a nationwide basis with a view to towards becoming the premier cancer treatment provider for animals. Under this initiative, PharmaCom BioVet, Inc. is pleased to announce that significant development progress has been made to establishing the first center. Management has recently been focusing on the logistics of starting the first center with respect to analysis of facilities, equipment, staffing and strategic partnerships. It is envisioned initial care center will be launched within a major veterinary research and care facility in a Missouri community. Further information of the location and opening date will be released by the company in due course.
ADVERTISEMENT
About Us:
PharmaCom BioVet, Inc. is quickly positioning itself to becoming the leader in specialized veterinary oncology (cancer treatment facilities for animals). PharmaCom BioVet Inc.'s management is planning the rollout of specialized Veterinary Oncology Treatment Centers that will be strategically located throughout the United States. The company has licensed a series of proprietary devices and compounds that will enable animals suffering from cancer a greater life expectancy and decreased suffering.
On behalf of the Board of Directors,
Mr. Gary Berthold
DISCLOSURE:
"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that are subject to risk and uncertainties, including, but not limited to, the impact of competitive products, product demand, market acceptance risks, fluctuations in operating results, political risk and other risks detailed from time to time in PharmaCom BioVet, Inc.'s filings with the Securities and Exchange Commission. These risks could cause PharmaCom BioVet, Inc.'s actual results to differ materially from those expressed in any forward-looking statements made by, or on behalf of, PharmaCom BioVet, Inc.
Contact:
Contacts:
PharmaCom BioVet, Inc.
Gary Berthold
(919) 572 6395
PHMB .0003 gettin smoked, volume alert, News!!!
PHMB News out this morning
Press Release Source: PharmaCom BioVet, Inc.
PharmaCom BioVet, Inc. Provides Update On Corporate Development
Tuesday March 10, 10:24 am ET
RALEIGH, NORTH CAROLINA--(MARKET WIRE)--Mar 10, 2009 -- PharmaCom BioVet, Inc. (Other OTC:PHMB.PK - News) is pleased to provide shareholders with a corporate update on the company's development within the field of specialized veterinary oncology. As previously announced, the company is undergoing a strategic plan establishing Veterinary Oncology Treatment Centers on a nationwide basis with a view to towards becoming the premier cancer treatment provider for animals. Under this initiative, PharmaCom BioVet, Inc. is pleased to announce that significant development progress has been made to establishing the first center. Management has recently been focusing on the logistics of starting the first center with respect to analysis of facilities, equipment, staffing and strategic partnerships. It is envisioned initial care center will be launched within a major veterinary research and care facility in a Missouri community. Further information of the location and opening date will be released by the company in due course.
ADVERTISEMENT
About Us:
PharmaCom BioVet, Inc. is quickly positioning itself to becoming the leader in specialized veterinary oncology (cancer treatment facilities for animals). PharmaCom BioVet Inc.'s management is planning the rollout of specialized Veterinary Oncology Treatment Centers that will be strategically located throughout the United States. The company has licensed a series of proprietary devices and compounds that will enable animals suffering from cancer a greater life expectancy and decreased suffering.
On behalf of the Board of Directors,
Mr. Gary Berthold
DISCLOSURE:
"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that are subject to risk and uncertainties, including, but not limited to, the impact of competitive products, product demand, market acceptance risks, fluctuations in operating results, political risk and other risks detailed from time to time in PharmaCom BioVet, Inc.'s filings with the Securities and Exchange Commission. These risks could cause PharmaCom BioVet, Inc.'s actual results to differ materially from those expressed in any forward-looking statements made by, or on behalf of, PharmaCom BioVet, Inc.
Contact:
Contacts:
PharmaCom BioVet, Inc.
Gary Berthold
(919) 572 6395
VSTN +47%
VSTN +46%
VSTN merger? French sovereign wealth fund takes stake in Valeo
8:03 AM ET 2/25/09 | Marketwatch
RELATED QUOTES
11:43 AM ET 2/25/09
Symbol Last % Chg
VLEEY
6.00 -0.83%
VC
0.13 -13.33%
Quotes delayed at least 15 minutes
LONDON (MarketWatch) -- France's sovereign wealth fund on Wednesday announced it had taken a stake in French auto parts group Valeo, a firm that has been targeted by a New York investment group pushing for a merger.
The FSI said it's taken an 8.3% stake in Valeo (VLEEY) and has 10.55% of the voting rights.
New York-based Pardus Capital Management, Valeo's top shareholder, has suggested the French firm merge with Visteon (VC), a rival auto parts maker in which Pardus also is the leading shareholder.
Pardus last May agreed not to exercise voting rights above 20% in Valeo and not sit on the board of Visteon or Delphi.
FSI said Valeo is a major European and world auto parts group and said Valeo's position in the sector is strategic.
The move comes as French President Nicolas Sarkozy has been accused of protectionism, notably for trying to get French automakers to lay off jobs only in foreign plants.
Valeo shares climbed 2.9% in Paris trade.
Posted by: pkripper Date: Wednesday, February 25, 2009 12:07:27 PM
In reply to: None Post # of 54
VSTN +33%
VSTN +25%
VSTN +20%, Just made thier payment, NO BK!!!!
http://www.reuters.com/article/rbssConsumerGoodsAndRetailNews/idUSN1052091520090310
Visteon makes interest payment
* Will manage through challenging environment
* Shares dip fractionally to 3.6 cents (Adds analyst's remarks, Ford comments background, bylines)
By David Bailey and Poornima Gupta
DETROIT, March 10 (Reuters) - Auto parts maker Visteon Corp(VSTN.PK), struggling amid the downturn in the auto industry, made a $16 million bond interest payment on Tuesday, a spokesman said.
"We continue to focus on managing through the current challenging operating environment," spokesman Jim Fisher said.
Visteon warned in February it was uncertain of staying in compliance with its debt covenants and was considering selling or eliminating some operations to raise cash.
Fitch said on Monday it thought a default by Visteon was imminent or inevitable, saying the supplier had "virtually no access" to outside capital.
Visteon, whose shares have plunged to 3.5 cents, has been among suppliers that have been considered at risk for bankruptcy by industry and debt analysts.
"All of their efforts have been overwhelmed," said Kip Penniman, credit analyst at KDP Investment Advisers. "I really thought they would file for Chapter 11 before they made this payment," he said.
Penniman, who has followed Visteon since its spinoff by Ford Motor Co (F.N) in 2000, said the interest payment may have been made for several reasons.
Visteon may have been unable to negotiate bankruptcy financing, it may be banking on support from Ford or the U.S. government, it could be attempting to sell all or part of the company or management may believe it can survive the downturn, Penniman said.
Ford spokesman Todd Nissen said Visteon was still a key supplier for Ford. He declined to say whether Ford had provided any assistance to Visteon, saying that Ford would not comment on any private dealings with its suppliers.
"We are in regular conversations with them," Nissen said. "If it makes sense for is to provide assistance to a supplier, we would do it."
Visteon also said in February it planned additional job cuts to help it cope with the downturn. It eliminated 9,300 jobs in 2008.
With automakers slashing North American production sharply from the fourth quarter of 2008 onward, the pressure on auto parts suppliers such as Visteon has been increasing. Continued
VSTN +20%, Just made thier payment, NO BK!!!!
http://www.reuters.com/article/rbssConsumerGoodsAndRetailNews/idUSN1052091520090310
Visteon makes interest payment
* Will manage through challenging environment
* Shares dip fractionally to 3.6 cents (Adds analyst's remarks, Ford comments background, bylines)
By David Bailey and Poornima Gupta
DETROIT, March 10 (Reuters) - Auto parts maker Visteon Corp(VSTN.PK), struggling amid the downturn in the auto industry, made a $16 million bond interest payment on Tuesday, a spokesman said.
"We continue to focus on managing through the current challenging operating environment," spokesman Jim Fisher said.
Visteon warned in February it was uncertain of staying in compliance with its debt covenants and was considering selling or eliminating some operations to raise cash.
Fitch said on Monday it thought a default by Visteon was imminent or inevitable, saying the supplier had "virtually no access" to outside capital.
Visteon, whose shares have plunged to 3.5 cents, has been among suppliers that have been considered at risk for bankruptcy by industry and debt analysts.
"All of their efforts have been overwhelmed," said Kip Penniman, credit analyst at KDP Investment Advisers. "I really thought they would file for Chapter 11 before they made this payment," he said.
Penniman, who has followed Visteon since its spinoff by Ford Motor Co (F.N) in 2000, said the interest payment may have been made for several reasons.
Visteon may have been unable to negotiate bankruptcy financing, it may be banking on support from Ford or the U.S. government, it could be attempting to sell all or part of the company or management may believe it can survive the downturn, Penniman said.
Ford spokesman Todd Nissen said Visteon was still a key supplier for Ford. He declined to say whether Ford had provided any assistance to Visteon, saying that Ford would not comment on any private dealings with its suppliers.
"We are in regular conversations with them," Nissen said. "If it makes sense for is to provide assistance to a supplier, we would do it."
Visteon also said in February it planned additional job cuts to help it cope with the downturn. It eliminated 9,300 jobs in 2008.
With automakers slashing North American production sharply from the fourth quarter of 2008 onward, the pressure on auto parts suppliers such as Visteon has been increasing. Continued